Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Conclusion:
The treatment effect of peginterferon beta1a in patients with relapsing–remitting MS is not expected to be attenuated by immunogenicity.

Source: Therapeutic Advances in Neurological Disorders - June 20, 2016 Category: Neurology Authors: White, J. T., Newsome, S. D., Kieseier, B. C., Bermel, R. A., Cui, Y., Seddighzadeh, A., Hung, S., Crossman, M., Subramanyam, M. Tags: Original Research Source Type: research